- Home
- MNOV vs ALXO Comparison
MNOV vs ALXO Comparison
Compare MNOV & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- ALXO
- Stock Information
- Founded
- MNOV 2000
- ALXO 2015
- Country
- MNOV United States
- ALXO United States
- Employees
- MNOV N/A
- ALXO 44
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- ALXO Health Care
- Exchange
- MNOV Nasdaq
- ALXO Nasdaq
- Market Cap
- MNOV 76.0M
- ALXO 79.7M
- IPO Year
- MNOV 2005
- ALXO 2020
- Fundamental
- Price
- MNOV $1.43
- ALXO $1.43
- Analyst Decision
- MNOV Strong Buy
- ALXO Strong Buy
- Analyst Count
- MNOV 2
- ALXO 6
- Target Price
- MNOV $7.00
- ALXO $3.30
- AVG Volume (30 Days)
- MNOV 3.0M
- ALXO 400.4K
- Earning Date
- MNOV 11-12-2025
- ALXO 11-07-2025
- Dividend Yield
- MNOV N/A
- ALXO N/A
- EPS Growth
- MNOV N/A
- ALXO N/A
- EPS
- MNOV N/A
- ALXO N/A
- Revenue
- MNOV $257,917.00
- ALXO N/A
- Revenue This Year
- MNOV N/A
- ALXO N/A
- Revenue Next Year
- MNOV N/A
- ALXO N/A
- P/E Ratio
- MNOV N/A
- ALXO N/A
- Revenue Growth
- MNOV N/A
- ALXO N/A
- 52 Week Low
- MNOV $1.13
- ALXO $0.40
- 52 Week High
- MNOV $2.48
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- MNOV 51.44
- ALXO 47.94
- Support Level
- MNOV $1.41
- ALXO $1.18
- Resistance Level
- MNOV $1.63
- ALXO $1.66
- Average True Range (ATR)
- MNOV 0.10
- ALXO 0.19
- MACD
- MNOV -0.01
- ALXO 0.01
- Stochastic Oscillator
- MNOV 6.93
- ALXO 60.66
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.